Biolog-id Awarded Innovation Partnership by the EFS
We are proud to announce that Biolog-id has been ranked first in an innovation partnership for the remote delivery of blood products by the Établissement Français du Sang (EFS).
As part of this tender, Biolog-id offered the Smart Access Kit, an innovative connected enclosure designed to ensure secured and optimized distribution of blood products.
“Thanks to its expertise in RFID technology and data management, Biolog-id provides a secure response to the challenges posed by staff shortages in remote areas, while ensuring enhanced continuity and efficiency in the blood supply chain,” commented Valérie Decleves, Chief Revenue Officer of Biolog-id for the EMEA region.
“The French Blood Establishment (EFS) is the sole collector and provider of blood products in France. With 3 million donations per year, its international reputation validates, on a large scale, the work carried out by our teams worldwide over the past several years,” added Remi Corlin, CEO of Biolog-id.
This is a major milestone for Biolog-id that will help drive its expansion across Europe, USA, India, and the Middle East.
About Biolog-id
Biolog-id develops value chain optimization solutions that create, collect, and consolidate high-quality data to deliver operational, business, and clinical impact for high-value, high-impact healthcare products. Biolog-id’s patented platform is used by numerous clients in the United States, Europe, the Middle East, India, and the Asia-Pacific region.
Website: www.biolog-id.com
Contact: contact@biolog-id.com
About the EFS
EFS is France’s public blood service. We are nearly 10,000 professionals—doctors, nurses, biologists, lab technicians, pharmacists, collection teams, researchers, and administrative staff—committed to a vital mission: providing health facilities and patients with essential blood products. We are present throughout the entire healthcare chain. Our expertise in medical biology and transplantation allows us to diagnose diseases and help treat over one million patients each year—those requiring transfusions or transplants—by collecting blood in France and delivering the blood products, tissues, and cells they need. We build on this know-how to innovate and develop medical procedures and treatments that will benefit patients as quickly as possible. We also help train healthcare professionals in France and around the world by sharing our expertise in blood science.
Thanks to the generosity of donors, we give blood the power to heal—making us a unique and essential player in the French healthcare system.
About Xerys Invest
Xerys Invest is a French private equity firm that invests in the Health and GreenTech sectors. The Xerys Funds, together with the company’s founder Jean-Claude Mongrenier, are the main shareholders of Biolog-id. Their mission is to support companies offering breakthrough innovations with global growth ambitions.
For more information: www.xerys.com; LinkedIn @Xerys.
